Literature DB >> 113814

Dopaminergic mechanisms and cognitive deficit in schizophrenia. A neurobiological model.

M H Joseph, C D Frith, J L Waddington.   

Abstract

A hypothesis is briefly discussed proposing that schizophrenic symptoms are due to a breakdown in a mechanism by which conscious attention is limited and directed. It is shown that this mechanism can be modelled in terms of a simple nerve network in which every channel inhibits all the others. Failure of this inhibition would cause the defect hypothesised to occur in schizophrenia. It is shown that if dopamine is given a central role as transmitter in such a network then the various predictions about the biochemistry of schizophrenia that follow are not only consistent with the evidence for the 'dopamine theory' of schizophrenia, but also with much of the evidence held to be contrary to that theory. While not purporting to be an experimentally validated description of schizophrenia, this model goes beyond the single amine theories of schizophrenia and links dysfunctions in amine systems with specific behavioural control mechanisms. Given the current state of knowledge, such models can make only limited predictions about the biochemistry of schizophrenia. However, an attempt to link behavioural and biochemical systems in this way will be crucial for the development of viable animal models of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 113814     DOI: 10.1007/bf00433561

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  53 in total

1.  Evidence for an inhibitory gabergic control of the meso-limbic dopamine neurons: possibility of improving treatment of schizophrenia by combined treatment with neuroleptics and gabergic drugs.

Authors:  K Fuxe; T Hökfelt; A Ljungdahl; L Agnati; O Johansson; M Perez de la Mora
Journal:  Med Biol       Date:  1975-06

2.  Time-dependent effects of phenothiazines on dopamine turnover in psychiatric patients.

Authors:  R M Post; F K Goodwin
Journal:  Science       Date:  1975-10-31       Impact factor: 47.728

3.  Excitation-mediating and inhibition-mediating dopamine-receptors: a new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data.

Authors:  A R Cools; J M Van Rossum
Journal:  Psychopharmacologia       Date:  1976-02-02

4.  Possible mechanisms involved in the stereotyped behavior elicited by amphetamine.

Authors:  P M Groves
Journal:  Biol Psychiatry       Date:  1977-06       Impact factor: 13.382

5.  GABAergic inhibition of neurons in the ventral tegmental area.

Authors:  P Wolf; H R Olpe; D Avrith; H L Haas
Journal:  Experientia       Date:  1978-01-15

Review 6.  Biochemical studies in schizophrenia.

Authors:  H Y Meltzer
Journal:  Schizophr Bull       Date:  1976       Impact factor: 9.306

7.  Serum prolactin levels in unmedicated schizophrenic patients.

Authors:  H Y Meltzer; E J Sachar; A G Frantz
Journal:  Arch Gen Psychiatry       Date:  1974-10

8.  Influence of family life on the course of schizophrenic disorders: a replication.

Authors:  G W Brown; J L Birley; J K Wing
Journal:  Br J Psychiatry       Date:  1972-09       Impact factor: 9.319

9.  Behavioral studies following lesions of the mesolimbic and mesostriatal serotonergic pathways.

Authors:  M A Geyer; A Puerto; D B Menkes; D S Segal; A J Mandell
Journal:  Brain Res       Date:  1976-04-23       Impact factor: 3.252

10.  Mechanism of the antipsychotic effect in the treatment of acute schizophrenia.

Authors:  E C Johnstone; T J Crow; C D Frith; M W Carney; J S Price
Journal:  Lancet       Date:  1978-04-22       Impact factor: 79.321

View more
  9 in total

1.  Role of monoamine pathways in the control of attention: effects of droperidol and methylphenidate in normal adult humans.

Authors:  C R Clark; G M Geffen; L B Geffen
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Role of monoamine pathways in attention and effort: effects of clonidine and methylphenidate in normal adult humans.

Authors:  C R Clark; G M Geffen; L B Geffen
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Facilitation of latent inhibition by haloperidol in rats.

Authors:  I Weiner; J Feldon
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

4.  Changes in the amounts of neurotransmitters released from the striatum and spontaneous motor activity in rats exposed to high doses of toluene.

Authors:  H Aikawa; T Yoshida; S Shigeta
Journal:  Environ Health Prev Med       Date:  1997-01       Impact factor: 3.674

5.  Differential effects of intra-accumbens and systemic amphetamine on latent inhibition using an on-baseline, within-subject conditioned suppression paradigm.

Authors:  A S Killcross; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Altered spatial profile of distraction in people with schizophrenia.

Authors:  Carly J Leonard; Benjamin M Robinson; Britta Hahn; Steven J Luck; James M Gold
Journal:  J Abnorm Psychol       Date:  2017-11

7.  Amphetamine-induced disruptions of latent inhibition are reinforcer mediated: implications for animal models of schizophrenic attentional dysfunction.

Authors:  A S Killcross; A Dickinson; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

Review 8.  Neuroleptics and psychic indifference: a review.

Authors:  D Healy
Journal:  J R Soc Med       Date:  1989-10       Impact factor: 18.000

Review 9.  Psychosis in Women: Time for Personalized Treatment.

Authors:  Marianna Mazza; Emanuele Caroppo; Domenico De Berardis; Giuseppe Marano; Carla Avallone; Georgios D Kotzalidis; Delfina Janiri; Lorenzo Moccia; Alessio Simonetti; Eliana Conte; Giovanni Martinotti; Luigi Janiri; Gabriele Sani
Journal:  J Pers Med       Date:  2021-12-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.